Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40ZST | ISIN: US59267L1070 | Ticker-Symbol:
NASDAQ
26.06.25 | 21:59
28,760 US-Dollar
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
METSERA INC Chart 1 Jahr
5-Tage-Chart
METSERA INC 5-Tage-Chart

Aktuelle News zur METSERA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.06.Metsera stock initiated at overweight by Wells Fargo on obesity drug6
13.06.Cantor Fitzgerald reiterates Metsera stock rating on strong MET-233i results4
12.06.Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results2
10.06.Metsera extends gains after early-stage trial data for obesity therapy2
09.06.Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data1
09.06.Metsera's Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med1
09.06.Metsera shares climb on early data for amylin-targeting obesity shot1
METSERA Aktie jetzt für 0€ handeln
09.06.Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punch2
09.06.Metsera shares soar on positive amylin candidate trial results2
09.06.Metsera posts weight loss data for amylin analog, teeing up monthly GLP-1 combo plans2
09.06.Metsera reports promising Phase 1 trial results for obesity treatment5
09.06.Metsera, Inc.: Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i973Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated...
► Artikel lesen
09.06.Metsera, Inc. - 8-K, Current Report4
05.06.Metsera, Inc.: Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association2
27.05.Cantor Fitzgerald maintains overweight on Metsera shares2
13.05.Metsera GAAP EPS of -$1.03 misses by $0.282
12.05.Metsera Posts Wider Loss In Q11
12.05.Metsera, Inc. - 8-K, Current Report4
12.05.Metsera, Inc. - 10-Q, Quarterly Report1
12.05.Metsera, Inc.: Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress404MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025 MET-233i, a monthly, ultra-long...
► Artikel lesen
Weiter >>
70 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1